Regorafenib plus sintilimab as a salvage treatment for microsatellite stable metastatic colorectal cancer: a single-arm, open-label, phase II clinical trial

Regorafenib plus sintilimab as a salvage treatment for microsatellite stable metastatic colorectal cancer: a single-arm, open-label, phase II clinical trial

Abstract Immune checkpoint inhibitors (ICIs) have limited efficacy in microsatellite stable (MSS) metastatic colorectal cancer (mCRC), and combination therapy needs to be further explored. In this single-arm, open-label, phase II trial (NCT04745130), we evaluate the efficacy and safety of the combin...

Full description

Saved in:
Bibliographic Details
Main Authors: Rui Liu, Zhi Ji, Xia Wang, Lila Zhu, Jiaqi Xin, Lijun Ma, Jiayu Zhang, Shaohua Ge, Le Zhang, Yuchong Yang, Tao Ning, Ming Bai, Jingjing Duan, Feixue Wang, Yansha Sun, Hongli Li, Ting Deng, Yi Ba, Jihui Hao
Format: Article
Language:English
Published: Nature Portfolio 2025-02-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-025-56748-3
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41467-025-56748-3

Similar Items